GNI encouraged by pirfenidone lung injury results
This article was originally published in Scrip
Executive Summary
GNI will take its pirfenidone product F647 into Phase III development in the middle of this year following what it saw as promising data from a Phase II trial in radiation therapy-induced lung injury.